Nexium for injection and infusion is indicated in adults for: • Gastric antisecretory treatment when the oral route is not possible, such as: - gastroesophageal reflux disease (GERD) in patients with esophagitis and/or severe symptoms of reflux. - healing of gastric ulcers associated with NSAID therapy. - prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk. • Prevention of rebleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers. Nexium for injection and infusion is indicated in children and adolescents aged 1-18 years for: • Gastric antisecretory treatment when the oral route is not possible, such as: - gastroesophageal reflux disease (GERD) in patients with erosive reflux esophagitis and/or severe symptoms of reflux.
Nexium tablets are indicated in adults for: Gastroesophageal Reflux Disease (GERD) – treatment of erosive reflux esophagitis. Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers. Treatment of Zollinger Ellison Syndrome Nexium tablets are indicated in adolescents from the age of 12 years for: Gastroesophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis
AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to GrĂ¼nenthal.
AstraZeneca has entered into an agreement with Pfizer Inc. for the over-the-counter (OTC) rights for Nexium (esomeprazole magnesium) currently approved...
Nexium tablets are indicated in adults for: Gastroesophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (GERD) In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori and - healing of Helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers. Patients requiring continued NSAID therapy - healing of gastric ulcers associated with NSAID therapy. - prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk. Treatment of Zollinger Ellison Syndrome Nexium tablets are indicated in adolescents from the age of 12 years for: Gastroesophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (GERD) In combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori
Nexium Control is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults.
Nexium oral suspension is primarily indicated for: Paediatric population Children 1-11 years old Gastroesophageal Reflux Disease (GERD) - treatment of endoscopically proven erosive reflux esophagitis - symptomatic treatment of gastroesophageal reflux disease (GERD) Children over 4 years of age In combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori . Adults and adolescents from the age of 12 years For indications in patients from the age of 12 years reference is made to the Nexium gastro-resistant tablet SmPC. Nexium oral suspension may also be used by patients having difficulty swallowing dispersed Nexium gastro-resistant tablets.